For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
The finding may open a whole new world in the study of Alzheimer's disease, said biophysicist Aneta Stefanovska.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback